Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. BFM (Berlin-Frankfurt-Münster) Relapse Study Group.

Presymptomatic central nervous system (CNS) treatment in children with a late isolated first bone marrow (BM) relapse of acute lymphoblastic leukemia (ALL) was based on intermediate-dose systemic and intrathecal (IT) methotrexate (MTX) in the multicenter trial, ALL-REZ BFM 85. Because this was associated with an excess of overt second CNS relapses, cranial radiotherapy (cRT) plus prolonged triple IT therapy with MTX, cytarabine, and prednisone was instituted during the course of the subsequent trial, ALL-REZ BFM 87. Results of children with or without cRT, but otherwise identical chemotherapy, are presented here. Between April 1985 and March 1990, 93 children with their first late isolated BM relapse of ALL were entered on protocols ALL-REZ BFM 85M and ALL-REZ BFM 87. An intensive 6-month phase of multiagent chemotherapy that included 8 courses of systemic MTX (1 g/m2) plus IT MTX was followed by 2 years of conventional maintenance therapy with daily 6-thioguanine and biweekly MTX. Children with bone marrow transplantation excluded, 73 were in complete remission at the end of intensive polychemotherapy, 40 of whom received fractionated cRT plus triple IT therapy during the following 6 months; 11 did not receive cRT but prolonged triple IT; 22 received neither cRT nor prolonged triple IT. Except for a higher percentage of children who had received cRT in front-line protocols (29 of 33 v 20 of 40), the patient groups without or with salvage cRT were comparable. Of 33 children without salvage cRT, 26 relapsed, compared with 21 of 40 who had received cRT (P < .05). The difference was solely attributable to second relapses with CNS involvement (10 of 33 v 1 of 40; P < .01). Estimated 6-year event-free survival rates were .18 for children without cRT and .46 for children with cRT (P < .01). In patients without cRT, no impact of prolonged IT therapy could be shown. The data suggest that second CNS prophylaxis with cRT and prolonged triple IT therapy in children with late isolated BM relapse of ALL is effective in preventing CNS relapses, in reducing the overall relapse rate, and in increasing the overall survival rate.

[1]  S. Smith,et al.  Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1993, Blood.

[2]  L. Robison,et al.  Second neoplasms after acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.

[3]  R Hartmann,et al.  Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. , 1991, Blood.

[4]  R. Mulhern,et al.  Late effects of antileukemic treatment. , 1988, Pediatric clinics of North America.

[5]  S. George,et al.  Second central nervous system prophylaxis in children with acute lymphoblastic leukemia who relapse after elective cessation of therapy. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Pullen,et al.  CNS prophylaxis in acute lymphoblastic leukemia. Comparison of two methods a southwest oncology group study , 1982, Cancer.

[7]  G. Henze,et al.  Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia. , 1993, Medical and pediatric oncology.

[8]  J. Shuster,et al.  Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. , 1991, Medical and pediatric oncology.

[9]  R. Sabbah,et al.  Effective prevention of central nervous system leukemia with intrathecal methotrexate and intrathecal methotrexate, cytosine arabinoside, and hydrocortisone in childhood acute lymphocytic leukemia. , 1990, Haematology and blood transfusion.

[10]  G. Henze,et al.  BFM group treatment results in relapsed childhood acute lymphoblastic leukemia. , 1990, Haematology and blood transfusion.

[11]  G. Henze,et al.  Risk of CNS relapse after systemic relapse of childhood acute lymphoblastic leukemia. , 1990, Haematology and blood transfusion.

[12]  G. Henze,et al.  Central nervous system relapse prevention in 1165 standard-risk children with acute lymphoblastic leukemia in five BFM trials. , 1990, Haematology and blood transfusion.

[13]  C. Pui,et al.  Cyclic combination chemotherapy for acute lymphoblastic leukemia recurring after elective cessation of therapy. , 1988, Medical and pediatric oncology.

[14]  P. Dyment,et al.  Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a pediatric oncology group study. , 1982, Blood.

[15]  V. Castel,et al.  [CNS prophylaxis in acute lymphoblastic leukemia (author's transl)]. , 1980, Anales espanoles de pediatria.